IOXILAN (400 MG)
- CAS NO.:107793-72-6
- Empirical Formula: C18H24I3N3O8
- Molecular Weight: 791.11
- MDL number: MFCD00867280
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-07-02 08:55:37
What is IOXILAN (400 MG)?
Absorption
Peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes. This can be accounted for by the dilution in the vascular and extravascular fluid compartments.
Toxicity
Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravascular contrast agents. Administration of any intravascular contrast agent should therefore be postponed in any patient with a known or suspected hepatic or biliary disorder who has recently received a cholecystographic contrast agent.
Other drugs should not be admixed with this product.
Pregnancy Category B
The Uses of IOXILAN (400 MG)
Nonionic iodinated contrast medium. Diagnostic aid (radiopaque medium).
Background
Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.
Indications
When administered intra-arterially, Ioxilan is indicated for the following diagnostic tests: cerebral arteriography (300 mgI/mL), coronary arteriography and left ventriculography (350 mgI/mL), visceral angiography(350 mgI/mL), aortography(350 mgI/mL), and peripheral arteriography(350 mgI/mL). When administered intravenously, Ioxilan is indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300 and 350 mgI/mL).
Definition
ChEBI: Ioxilan is an amidobenzoic acid.
brand name
Oxilan (Guerbet).
Pharmacokinetics
As with other iodinated contrast agents the degree of contrast enhancement is directly related to the iodine content in the administered dose.
Metabolism
There is no evidence for metabolism.
Properties of IOXILAN (400 MG)
Boiling point: | 827.8±65.0 °C(Predicted) |
Density | 2.205±0.06 g/cm3(Predicted) |
storage temp. | Store at -20°C |
solubility | DMSO: ≥ 250 mg/mL (316.01 mM) |
pka | 11.47±0.46(Predicted) |
form | Solid |
color | White to off-white |
EPA Substance Registry System | 1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo- (107793-72-6) |
Safety information for IOXILAN (400 MG)
Computed Descriptors for IOXILAN (400 MG)
New Products
6-Bromo 2-Iodo Indole Pyridine 2,4,6-Tricarboxaldehyde Fosfomycin EP impurity D Ivermectin EP Impurity B Rimegepant Impurity 3 Tubulysin E 2,2-diethoxyethanethioamide Tubulysin I 2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol ethanedioate (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine Imeglimin Hydrochloride IH Calcium Sodium Phosphosilicate IH 2-(1-(Mercaptomethyl) cyclopropyl) acetonitrile 2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol 1-(4-Chlorophenyl)piperidin-2-one Methyl 4-amino-3-(piperidin-1-yl)benzoate 4,8-dibromo-5H-[1,2,3]triazolo[4',5':4,5]benzo[1,2-c][1,2,5]thiadiazole 2-(3,5-Di-tert-butylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Methyl 4-amino-3-(4-phenylpiperazin-1-yl)benzoate 3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dione 6-Hydroxyisoquinoline 4-fluoro-1-methyl-pyrazole 3,3-dimethyl-2-oxo-, methyl ester 5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4-carbonitrileRelated products of tetrahydrofuran
You may like
-
3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dioneView Details
952145-70-9 -
1262243-12-8View Details
1262243-12-8 -
Rimegepant Impurity 3View Details
-
Sidchem 730View Details
-
Sidchem BT 20View Details
-
1572177-89-9View Details
1572177-89-9 -
6390-09-6View Details
6390-09-6 -
6-Bromo indoleView Details